Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
The New England Journal of Medicine|June 5, 2023
Survival with Axicabtagene Ciloleucel in Large B-Cell LymphomaJason R Westin, Olalekan O Oluwole, Marie José Kersten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2023
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T ConsortiumYucai Wang, Preetesh Jain, Frederick L Locke, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 13, 2019
Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host diseaseKatelyn Paz, Ryan Flynn, Jing Du, et al.
Nature Medicine|September 13, 2022
Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapyZinaida Good, Jay Y Spiegel, Bita Sahaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2024
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumMichael D Jain, Jay Y Spiegel, Loretta J Nastoupil, et al.
Blood|April 18, 2024
Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicityFrederick L Locke, Tanya Siddiqi, Caron A Jacobson, et al.
Blood|February 23, 2023
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphomaSattva S Neelapu, Caron A Jacobson, Armin Ghobadi, et al.
The New England Journal of Medicine|December 10, 2021
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell LymphomaFrederick L Locke, David B Miklos, Caron A Jacobson, et al.
Blood|January 29, 2021
CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphomaJohn H Baird, Matthew J Frank, Juliana Craig, et al.
The Lancet. Oncology|December 7, 2018
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trialFrederick L Locke, Armin Ghobadi, Caron A Jacobson, et al.
Pageof 12